---
title: "Bright Minds Biosciences Inc. (DRUG.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/DRUG.US.md"
symbol: "DRUG.US"
name: "Bright Minds Biosciences Inc."
industry: "Biotechnology"
datetime: "2026-05-21T14:22:26.613Z"
locales:
  - [en](https://longbridge.com/en/quote/DRUG.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/DRUG.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/DRUG.US.md)
---

# Bright Minds Biosciences Inc. (DRUG.US)

## Company Overview

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [brightmindsbio.com](https://brightmindsbio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -40.84 | 530 | - | - | - |
| PB | 3.66 | 280 | 12.86 | 10.77 | 6.16 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-20T04:00:00.000Z

Total Analysts: **7**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 6 | 86% |
| Overweight | 1 | 14% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 54.75 |
| Highest Target | 93.00 |
| Lowest Target | 93.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/DRUG.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/DRUG.US/norm.md)
- [Related News](https://longbridge.com/en/quote/DRUG.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/DRUG.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**